Celon launches an emulsion-based drug to treat the deadly Black Fungus in COVID–19 patients!

Celon develops an alternative emulsion-based formulation in 

three weeks, to overcome the short supply of Liposomal Amphotericin B

Hyderabad, May 31st, 2021: Hyderabad based specialty biopharmaceutical manufacturer, Celon Laboratories, announced the launch of an alternative drug – Amphotericin B Emulsion, for the treatment of Mucormycosis, commonly known as Black Fungus. The drug is set to provide much needed respite to patients reeling under the severe impact of the second wave of COVID-19 and the resultant Black Fungus. 

Amphotericin B, is crucial to the treatment of Mucormycosis, of which a sudden resurgence is being witnessed off late among COVID-19 patients, across India. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany — lipoids. To bypass the bottleneck caused by this sourcing obstacle and increase production of this medication, Celon developed an alternative, an emulsion-based formulation. 

Exhaustively developed by Celon’s in-house R&D team in a record three weeks, the emulsion-based formulation will provide leading hospitals and COVID-19 treatment centers with increased resources to treat the Black Fungus. Celon will manufacture 10,000 vials per day, which will ensure relief for approximately 6,000 patients monthly. 

Celon Labs’ Managing Director, Mr. M. Nagesh Kumar, spoke of Celon’s role during India’s second wave of COVID-19: “Celon Labs is deeply committed to supporting the ongoing efforts to combat the Covid-19 pandemic during this deadly second wave and to save as many lives as possible. The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. The company will start supplying the domestic market soon.”

Additionally, the Chairman of Celon, Mr. Hocine Sidi-Said, expressed his gratitude to employees for achieving this important milestone: “I am delighted to see that Celon Labs has mobilized its talents and expertise to swiftly respond to this pressing medical need. I am grateful to the team at Celon Labs who have made the launch of Amphotericin B Emulsion possible.”

About Celon

Celon Laboratories Private Limited engages in the manufacturing, marketing, and distribution of specialty biopharmaceutical products specific to oncology and critical care segments. Additionally, Celon manufactures special technology-based products developed in-house, including depots, nano-particulate, and other liposomal formulations. The company employs 600 people and commercializes its products within India as well as over 40 additional markets across the globe. Celon is owned by the London-based KELIX bio, which is backed by CDC Group, the United Kingdom’s publicly-owned impact investor, Development Partners International (DPI), through its ADP III fund and the European Bank for Reconstruction and Development (EBRD). 

Celon launches an emulsion-based drug to treat the deadly Black Fungus in COVID–19 patients!

Celon develops an alternative emulsion-based formulation in 

three weeks, to overcome the short supply of Liposomal Amphotericin B

Hyderabad, May 31st, 2021: Hyderabad based specialty biopharmaceutical manufacturer, Celon Laboratories, announced the launch of an alternative drug – Amphotericin B Emulsion, for the treatment of Mucormycosis, commonly known as Black Fungus. The drug is set to provide much needed respite to patients reeling under the severe impact of the second wave of COVID-19 and the resultant Black Fungus. 

Amphotericin B, is crucial to the treatment of Mucormycosis, of which a sudden resurgence is being witnessed off late among COVID-19 patients, across India. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany — lipoids. To bypass the bottleneck caused by this sourcing obstacle and increase production of this medication, Celon developed an alternative, an emulsion-based formulation. 

Exhaustively developed by Celon’s in-house R&D team in a record three weeks, the emulsion-based formulation will provide leading hospitals and COVID-19 treatment centers with increased resources to treat the Black Fungus. Celon will manufacture 10,000 vials per day, which will ensure relief for approximately 6,000 patients monthly. 

Celon Labs’ Managing Director, Mr. M. Nagesh Kumar, spoke of Celon’s role during India’s second wave of COVID-19: “Celon Labs is deeply committed to supporting the ongoing efforts to combat the Covid-19 pandemic during this deadly second wave and to save as many lives as possible. The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. The company will start supplying the domestic market soon.”

Additionally, the Chairman of Celon, Mr. Hocine Sidi-Said, expressed his gratitude to employees for achieving this important milestone: “I am delighted to see that Celon Labs has mobilized its talents and expertise to swiftly respond to this pressing medical need. I am grateful to the team at Celon Labs who have made the launch of Amphotericin B Emulsion possible.”

About Celon

Celon Laboratories Private Limited engages in the manufacturing, marketing, and distribution of specialty biopharmaceutical products specific to oncology and critical care segments. Additionally, Celon manufactures special technology-based products developed in-house, including depots, nano-particulate, and other liposomal formulations. The company employs 600 people and commercializes its products within India as well as over 40 additional markets across the globe. Celon is owned by the London-based KELIX bio, which is backed by CDC Group, the United Kingdom’s publicly-owned impact investor, Development Partners International (DPI), through its ADP III fund and the European Bank for Reconstruction and Development (EBRD). 

For More information please contact: 9959154371 / 9963980259

Leave a Comment

Your email address will not be published. Required fields are marked *